Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.53 USD

86.53
3,439,683

-1.06 (-1.21%)

Updated Nov 15, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals

Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.

Boston Scientific's (BSX) ICM System Receives FDA Approval

Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.

Trina Mukherjee headshot

Medical Products Industry's Near-Term Outlook Lacks Spark

AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.

Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod

Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.

Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod

Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.

How Has BSX Performed 30 Days Post Earnings

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PETQ vs. BSX: Which Stock Should Value Investors Buy Now?

PETQ vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline

The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.

Boston Scientific (BSX) Q1 Earnings Miss Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of -15.15% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Apr 29: BSX, ALGN & More

Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?

Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.

Analysts Estimate Boston Scientific (BSX) to Report a Decline in Earnings: What to Look Out for

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sriparna Ghosal headshot

3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1

Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.

The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's

The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's

Sheraz Mian headshot

Top Research Reports for Tesla, Zoetis, Target

Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Zoetis (ZTS) and Target (TGT).

New Buyouts Aid Boston Scientific Amid Coronavirus Crisis

The current economic turbulence due to the coronavirus outbreak is massively causing depreciation of Boston Scientific's (BSX) stock.

Kevin Cook headshot

Bull of the Day: Edwards Lifesciences (EW)

While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Sreyoshi Mukherjee headshot

Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show

The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories

Urmimala Biswas headshot

Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt

S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.

Neovasc (NVCN) Releases Update on Reducer and Tiara Products

Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

Boston Scientific (BSX) Down 12.9% Since Last Earnings Report: Can It Rebound?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.